Brought to you by WBIW News and Network Indiana
Last updated on Monday, April 17, 2017
(INDIANAPOLIS) - Eli Lilly says U.S. regulators have rejected its much-anticipated pill for the immune disorder rheumatoid arthritis, the drugmaker’s second drug development setback since November.
The Food and Drug Administration said in a letter to the company that additional data from patient tests would be needed to better understand safety concerns and to determine the most appropriate doses, Lilly announced Friday. Lilly said it will work with the FDA on a plan to eventually get the drug, baracitinib, approved for U.S. patients.
In November, Lilly's experimental Alzheimer's medicine flopped in a closely watched patient test.
The drug, which has the proposed brand name Olumiant and is approved for use in Europe, was expected to be a big seller in part because most other new rheumatoid arthritis drugs are injected.
1340 AM WBIW welcomes comments and suggestions by calling 812.277.1340 during normal business hours or by email at comments@wbiw.com
© Ad-Venture Media, Inc. All Rights Reserved.